TURP versus EchoLaser transperineal laser ablation (TPLA) for men with urinary symptoms from benign prostate obstruction
Official title: Randomized Clinical Trial Comparing Transurethral Prostate Resection (TURP) and Echolaser Soractelite-Transperineal Laser Ablation (TPLA ) in Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction
Run by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · NCT07289243 · Data updated 2026-11-12
This will test whether EchoLaser transperineal laser ablation (TPLA) works as well as standard TURP to reduce urinary symptoms in men with an enlarged prostate.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 85 Years |
| Sex | Men only |
| Enrollment | 80 (estimated) |
| Sponsor | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari Academic / other |
| Locations | 2 sites (Bari, ITALY/Bari and 1 other locations) |
| Status | Recruiting |
| Started | July 14, 2024 |
| Main results expected | December 25, 2025 |
| Study ends | December 25, 2026 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT07289243 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult men with bothersome lower urinary tract symptoms due to benign prostatic obstruction, IPSS ≥8, prostate volume 40–80 mL, and who have not achieved symptom control with medical therapy are the ideal candidates.
✕Probably not a fit
Patients with prior prostate surgery, indwelling bladder catheters, bladder stones or tumors, active urinary or seminal infections, urethral strictures, or neurologic bladder dysfunction are excluded and unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized clinical comparison, conducted at Policlinico di Bari, will assign men with lower urinary tract symptoms from benign prostatic obstruction to either standard transurethral resection of the prostate (TURP) or EchoLaser Soractelite transperineal laser ablation (TPLA). Eligible participants have IPSS ≥8, prostate volume 40–80 mL, and have not had successful medical therapy. The primary outcome is non-inferiority of TPLA versus TURP measured by change in IPSS score, with additional outcomes likely to include complications, urinary flow, and recovery metrics. Patients with prior prostate surgery, indwelling catheters, bladder stones or tumors, active infections, urethral strictures, or neurologic bladder dysfunction are excluded.
Why it matters
Potential benefit: If successful, TPLA could offer similar symptom relief to TURP with a less invasive approach and potentially faster recovery or fewer procedure-related complications.
How similar studies have gone: Minimally invasive prostate ablation techniques have shown promising symptom improvements in prior work, and small series of transperineal laser ablation report favorable results, but randomized head-to-head evidence versus TURP remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Lower urinary tract symptoms (IPSS \>= 8); * Poor efficacy after at least six months of medical therapy or intolerance to medical treatment for BPH; * Prostate volume: 40ml-80ml; * Ability to give informed consent. Exclusion Criteria: * Previous surgery for benign prostatic hyperplasia; * Indwelling bladder catheter or intermittent bladder catheterization; * Diagnosis of bladder stones; * Recurrent urinary tract infections or intraprostatic abscesses; * Severe detrusor hypocontractility or acontractility; * Hydronefrosis due to urinary retention; * Urethral strictures or diagnosis of neurogenic bladder; * Diagnosis of bladder cancer; * Diagnosis or clinical suspicion of prostate cancer.
Where it's running
-
UOC Urologia e Trapianti di Rene Policlinico di Bari
Bari, ITALY/Bari, Italy Recruiting -
UOC Urologia e Trapianti di Rene Policlinico di Bari
Bari, ITALY/Bari, Italy Active not recruiting
Study contacts
- Study coordinator: Marcello MZ Zingarelli, medicine and surgery
- Email: marcellozingarelli86@gmail.com
- Phone: +393405135446
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GenSci142 as a vaginal treatment for bacterial vaginosis
This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.
-
Adding tislelizumab with or without the probiotic Probio-M9 to pre-surgery chemoradiation for pMMR/MSS locally advanced rectal cancer.
This will see if adding the PD-1 drug tislelizumab, with or without the probiotic Probio-M9, to standard pre-surgery chemoradiation helps adults with pMMR/MSS locally advanced rectal cancer.
-
High-energy laser treatment for thumb osteoarthritis (rhizarthrosis)
This trial will test whether high-energy laser therapy using the THEAL Ixyon XP can reduce pain and improve function in people with early-stage thumb base osteoarthritis.
-
Very low-energy ketogenic program for adults with type 1 diabetes and obesity using an automated insulin system
This will test whether a 4-week very low-energy ketogenic diet delivered with meal replacements can help adults with type 1 diabetes and obesity who use an advanced hybrid closed‑loop insulin system lose weight safely.
-
Shock Waves for Knee Osteoarthritis
This study tests whether shock wave therapy plus home exercise helps people with knee osteoarthritis more than exercise alone.
-
High Energy Laser Therapy for a Grade III A Lower-Limb Muscle Tear
This study tests whether using high-energy laser therapy in addition to exercise helps people with a grade III A muscle tear in the legs recover faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.